NCOR2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL164803	0.67	12/20
SCHEMBL164802	0.62	11/20
Largazole Thiol (SCHEMBL72077)	1.00	9/20
SCHEMBL71351	0.85	9/20
Panobinostat (SCHEMBL164801)	1.00	8/20
Panobinostat (SCHEMBL183197)	1.00	8/20
SCHEMBL71678	0.82	8/20
SCHEMBL71104	0.70	8/20
Largazole (SCHEMBL71330)	1.00	7/20
Largazole (SCHEMBL91139)	1.00	7/20
SCHEMBL70561	0.81	7/20
SCHEMBL71365	0.79	7/20
SCHEMBL71340	0.82	6/20
SCHEMBL29911	0.45	6/20
SCHEMBL29912	0.45	6/20
SCHEMBL29913	0.45	6/20
SCHEMBL29914	0.45	6/20
SCHEMBL70584	0.60	5/20
SCHEMBL192409	0.52	5/20
SCHEMBL192410	0.52	5/20

Clinical trials — most relevant to NCOR2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical Role of Testosterone and Dihydrotestosterone and Which of Them Should be Inhibited in COVID-19 Patients - A Double-edged Sword?	PHASE4	UNKNOWN
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room	PHASE2/PHASE3	COMPLETED
Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.	PHASE3	COMPLETED
Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus	PHASE3	COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer	PHASE2	UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.	PHASE2	UNKNOWN
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer	PHASE1/PHASE2	RECRUITING
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Fibrates in Pediatric Cholestasis	PHASE2	COMPLETED
A Prevention Trial in Subjects at High Risk for Breast Cancer	PHASE2	COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Preoperative Bexarotene Treatment for Cushing's Disease	PHASE1/PHASE2	UNKNOWN
RORC Genetic Polymorphism of Rheumatoid Arthritis	nan	COMPLETED
Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women	nan	COMPLETED
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas	nan	ACTIVE_NOT_RECRUITING
Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer	nan	UNKNOWN
Thermogenic Silencer Regulatory Factors in Humans	nan	ACTIVE_NOT_RECRUITING
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer	nan	COMPLETED
Role of Obeticholic Acid in the Patients of NAFLD With Raised ALT	nan	COMPLETED
Tecfidera Diffusion Tensor Imaging	nan	COMPLETED
Evaluation of the Predictive Effect of Inflammatory Markers in MI Patients	nan	UNKNOWN
Effects of Losartan on Insulin Sensitivity and Secretion in Type 2 Diabetes and Nephropathy	nan	COMPLETED
Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy	nan	NOT_YET_RECRUITING
Metabolic Flexibility in Patients With Early Triple-negative Breast Cancer	nan	ACTIVE_NOT_RECRUITING
Precision High-Intensity Training Through Epigenetics (PHITE)	nan	COMPLETED
Assessing the Effects of Alfacalcidol Intake on Expression of Involed Gene in Metabolism in Obese Subjects	nan	UNKNOWN
Nasturtium (Tropaeolum Majus L) Intake and Biochemical Parameters in Pre-diabetic Subjects in Bogota Colombia	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NCOR2 binder may also engage these)

Protein	Name	Similarity
Q9WU42	—	1.000	Q9WU42 →
Q60974	—	0.996	Q60974 →
Q4KKX4	—	0.995	Q4KKX4 →
NCOR1	Nuclear receptor corepressor 1	0.992	landscape →
Q8QG78	—	0.987	Q8QG78 →
Q96N64	—	0.986	Q96N64 →
BRD8	Bromodomain-containing protein 8	0.984	landscape →
P49140	—	0.983	P49140 →
Q9Z2D6	—	0.983	Q9Z2D6 →
P12755	—	0.982	P12755 →
Q9TUG2	—	0.982	Q9TUG2 →
Q00566	—	0.982	Q00566 →
Q5XJV7	—	0.981	Q5XJV7 →
Q69Z61	—	0.981	Q69Z61 →
Q8R3B7	—	0.981	Q8R3B7 →
Q96SB3	—	0.981	Q96SB3 →
B3KU38	—	0.980	B3KU38 →
Q60698	—	0.980	Q60698 →
O54972	—	0.980	O54972 →
A0A088MLT8	—	0.980	A0A088MLT8 →
O00287	—	0.979	O00287 →
Q9UGU5	—	0.979	Q9UGU5 →
Q5R6Y9	—	0.979	Q5R6Y9 →
Q95LG8	—	0.979	Q95LG8 →
Q8K2W6	—	0.979	Q8K2W6 →
F7AQ22	—	0.979	F7AQ22 →
MECP2	Methyl-CpG-binding protein 2	0.979	landscape →
A0JPQ7	—	0.978	A0JPQ7 →
Q6R891	—	0.978	Q6R891 →
Q4LE39	—	0.978	Q4LE39 →